Literature DB >> 2605847

F-18 fluorodeoxyglucose: its potential in differentiating between stress fracture and neoplasia.

R Paul1, A Ahonen, P Virtama, A Aho, T Ekfors.   

Abstract

F-18 fluorodeoxyglucose (FDG) accumulates into regions of enhanced glucose uptake and metabolism such as the brain, heart, and malignant tumors. The clinical usefulness of this positron-emitting radiopharmaceutical is illustrated in a case where the clinical picture and CT indicated a malignant bone lesion in the clavicle. Histologically a stress fracture was found secondary to chronic strain on the clavicle. On follow-up the lesion's course was benign. Planar imaging with F-18 FDG was performed twice during follow-up, and on both occasions there was no accumulation of radioactivity over the suspicious area, indicating normal glucose consumption. This case demonstrates the differential diagnostic potential of F-18 FDG and shows that clinically useful information may be obtained without a position emission tomograph.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2605847     DOI: 10.1097/00003072-198912000-00010

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

1.  Bilateral stress fracture of the clavicle.

Authors:  E Calvo; D Fernández-Yruegas; L Alvarez; J C de Lucas; C Vallejo
Journal:  Skeletal Radiol       Date:  1995-11       Impact factor: 2.199

2.  Rapid normalization of osseous FDG uptake following traumatic or surgical fractures.

Authors:  Hongming Zhuang; Joseph W Sam; Thomas K Chacko; Paulo S Duarte; Marc Hickeson; Qi Feng; Kozaim Z Nakhoda; Liang Guan; Phillip Reich; Shirley M Altimari; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-22       Impact factor: 9.236

3.  Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.

Authors:  D-S Shin; O-J Shon; S-J Byun; J-H Choi; K-A Chun; I-H Cho
Journal:  Skeletal Radiol       Date:  2008-02-29       Impact factor: 2.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.